Alzheimer's disease
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - aged between 65-85 years. - without a previous diagnosis of cognitive impairment - a reliable informant - capable to speak Dutch;Additional criteria applied for the specific subpopulations: Subpopulation 1) Online * - Visitors of the online platform * - CANTAB score below the pre-fixed cut-off (adjusted by age and education) on the online cognitive tests. The cut-off will be determined in association with Cambridge Cognition based on already collected data in participants with normal cognition, MCI and dementia.;Subpopulation 2) Open house or event * - Visitors of an open house or event which are recruited by advertisements or via Hersenonderzoek.nl. * Any of the following: - MMSE between 20-27 or - FSCRT total score 10 - DSDRS 7-10 + 3 positive answers to SCD questions.
Exclusion criteria
Exclusion criteria: - Severe visual or hearing impairment that could interfere with the assessment. - History of traumatic brain injury involving loss of consciousness. - History of stroke (symptoms lasting more than 24 hours), epilepsy, demyelinating disease, parkinsonism, CNS infection. - Current symptoms of major depression. - Presence of severe metabolic or systemic disease that could be responsible for the cognitive symptoms in the opinion of the investigator. - Treatment with psychotropic medications that could significantly interfere with cognition in the opinion of the investigator. - A previous diagnosis of cognitive impairment. - Any contraindication to undergo MRI (claustrophobia, incompatible pacemakers, metallic medical devices, etc).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Risk for Alzheimer dementia, based on extensive evaluation using cognition, biomarkers, and traditional risk factors (genetic and environmental). | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the cost-effectivity (of recruitment and pre-screening) of four different subpopulations to detect individuals with prodromal/mild AD dementia within the Netherlands. In addition, cost-effectivity will be compared with findings in the other participating sites in other European countries. | — |
Countries
Netherlands
Outcome results
None listed